|
KMID : 0338420230380030382
|
|
The Korean Journal of Internal Medicine
2023 Volume.38 No. 3 p.382 ~ p.392
|
|
|
Corticosteroid outcome may be dependent of duration of use in severe COVID-19
|
|
Kim Jin-Hyoung
Na Yong-Sub
Lee Song-I
Moon Youn-Young
Hwang Beom-Seuk
Baek Ae-Rin
Kim Won-Young
Lee Bo-Young
Seong Gil-Myeong
Baek Moon-Seong
|
|
|
Abstract
|
|
|
Background/Aims: For patients hospitalized with coronavirus disease 2019 (COVID-19) who require supplemental oxygen, the evidence of the optimal duration of corticosteroid is limited. This study aims to identify whether long-term use of corticosteroids is associated with decreased mortality.
Methods: Between February 10, 2020 and October 31, 2021, we analyzed consecutive hospitalized patients with COVID-19 with severe hypoxemia. The patients were divided into short-term (≤ 14 days) and long-term (> 14 days) corticosteroid users. The primary outcome was 60-day mortality. We performed propensity score (PS) analysis to mitigate the effect of confounders and conducted Kaplan-Meier curve analysis.
Results: There were 141 (52%) short-term users and 130 (48%) long-term corticosteroid users. The median age was 68 years and the median PaO2/FiO2 at admission was 158. Of the patients, 40.6% required high-flow nasal cannula, 48.3% required mechanical ventilation, and 11.1% required extracorporeal membrane oxygenation. The overall 60-day mortality rate was 23.2%, and that of patients with hospital-acquired pneumonia (HAP) was 22.9%. The Kaplan-Meier curve for 60- day survival in the PS-matched cohort showed that corticosteroid for > 14 days was associated with decreased mortality (p = 0.0033). There were no significant differences in bacteremia and HAP between the groups. An adjusted odds ratio for the risk of 60-day mortality in short-term users was 5.53 (95% confidence interval, 1.90?18.26; p = 0.003).
Conclusions: For patients with severe COVID-19, long-term use of corticosteroids was associated with decreased mortality, with no increase in nosocomial complications. Corticosteroid use for > 14 days can benefit patients with severe COVID-19.
|
|
|
KEYWORD
|
|
|
COVID-19, Steroids, Oxygen inhalation therapy, Respiration, Artificial, Mortality
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|